Investor Alert

Market Pulse Archives

Dec. 13, 2019, 7:12 a.m. EST

Horizon Therapeutics halted for FDA advisory committee meeting on treatment for thyroid eye disease

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Horizon Therapeutics PLC (HZNP)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Horizon Therapeutics Plc shares /zigman2/quotes/206690250/composite HZNP -0.07% were halted in premarket trade Friday, ahead of a U.S. Food and Drug Administration advisory committee meeting to discuss a treatment for Thyroid Eye Disease, a serious autoimmune disorder. The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet at 8 a.m. Eastern to discuss teprotumumab, an investigational medicine. The meeting is scheduled to run to 4 p.m. Thyroid Eye Disease often affects patients living with hyperthyroidism or Graves' disease, and can cause long-term damage to eyes, including proptosis, or eye bulging, strabismus, or misalignment of the eyes, and diplopia, or double vision, and in extreme cases can lead to blindness. Teprotumumab has received Priority Review, Orphan Drug and Fast Track and Breakthrough designations from the FDA. Horizon shares have gained 68% in 2019, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.54% has gained 26%.

US : U.S.: Nasdaq
$ 87.35
-0.06 -0.07%
Volume: 1.77M
Jan. 27, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$19.83 billion
Rev. per Employee
-23.42 -0.54%
Volume: 3.04B
Jan. 27, 2022 5:00p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.